Literature DB >> 8947062

The nonhospital costs of care of patients with CF in The Netherlands: results of a questionnaire.

M F Wildhagen1, J B Verheij, J G Verzijl, J Gerritsen, W Bakker, H B Hilderink, L P ten Kate, T Tijmstra, L Kooij, J D Habbema.   

Abstract

Cystic fibrosis (CF) causes a relatively high medical consumption. A large part of the treatment takes place at home. Because data regarding nonhospital care are lacking, we wished to determine the costs of care of patients with CF outside the hospital. A questionnaire was sent to 73 patients with CF from two Dutch hospitals (response rate 64%, 14 children and 33 adults). Average consumption and average costs per patient per year were calculated for children and adults for six categories: nonhospital medical care; domestic help; diet; travelling because of CF; medication; and devices and special facilities at home, work or school. The average nonhospital costs of care amounted to Pounds 4,641 per child per year (range Pounds 712-13,269) and Pounds 10,242 per adult (range Pounds 1,653-26,571). Nonhospital medical care for children and adults accounted for, respectively, 8 and 5% of these costs, domestic help for 15 and 9%, diet for 10 and 7%, travelling because of CF for 4 and 8%, medication for 63 and 67%, and devices and special facilities at home, work or school for 1 and 4%. Nonhospital costs of care of cystic fibrosis are very high and amount to 50% of the total (medical and nonmedical) lifetime costs of cystic fibrosis.

Entities:  

Mesh:

Year:  1996        PMID: 8947062     DOI: 10.1183/09031936.96.09112215

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  8 in total

1.  Costs, effects, and savings of screening for cystic fibrosis gene carriers.

Authors:  M F Wildhagen; H B Hilderink; J G Verzijl; J B Verheij; L Kooij; T Tijmstra; L P ten Kate; J D Habbema
Journal:  J Epidemiol Community Health       Date:  1998-07       Impact factor: 3.710

Review 2.  Dornase alfa. A review of pharmacoeconomic and quality-of-life aspects of its use in cystic fibrosis.

Authors:  K L Goa; H Lamb
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

3.  Hospitalisation costs of cystic fibrosis.

Authors:  Jonas Schreyögg; Helge Hollmeyer; Miriam Bluemel; Doris Staab; Reinhard Busse
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  [Drug treatment of cystic fibrosis - cost patterns and savings potential for outpatient treatment].

Authors:  Christoph T Baltin; Christina Smaczny; Thomas O Wagner
Journal:  Med Klin (Munich)       Date:  2011-01-16

Review 5.  Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies.

Authors:  Christian Krauth; Noushin Jalilvand; Tobias Welte; Reinhard Busse
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

6.  [Cost analysis for ambulatory treatment of cystic fibrosis patients in Germany. Overview of the prospective study results].

Authors:  Daniela Eidt; Thomas Mittendorf; Thomas O F Wagner; Andreas Reimann; J-Matthias Graf von der Schulenburg
Journal:  Med Klin (Munich)       Date:  2009-07-18

Review 7.  Exacerbations in cystic fibrosis: 2 . prevention.

Authors:  Scott C Bell; Philip J Robinson
Journal:  Thorax       Date:  2007-08       Impact factor: 9.139

8.  The Potential of Self-Management mHealth for Pediatric Cystic Fibrosis: Mixed-Methods Study for Health Care and App Assessment.

Authors:  Antonio Martinez-Millana; Annabel Zettl; Jacqueline Floch; Joaquim Calvo-Lerma; Jose Luis Sevillano; Carmen Ribes-Koninckx; Vicente Traver
Journal:  JMIR Mhealth Uhealth       Date:  2019-04-18       Impact factor: 4.773

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.